The Use of EDX Fluorescence Spectrometry for Pharmaceutical Elemental Impurity Analysis Based on USP<735>
New guidelines governing the analysis of elemental impurities in pharmaceuticals are being implemented. Toxic heavy metals and residual metal catalysts may exist in the raw materials of Active Pharmaceutical Ingredients (APIs) or be added during the manufacturing process. These impurities may be a risk to human health.
This white paper demonstrates that X-ray Fluorescence (XRF) is capable of performing elemental impurity analysis of the above 12 elements in various pharmaceutical materials, such as Cellulose, Talc and a Mixture of Cellulose, Talc and TiO2, by the calibration curve method using water solution standard samples, and verifying the qualification of USP <735>.
Related White Papers
Analysis of Microplastics Using Mobile FTIR and FTIR ImagingWhite Paper
Identifying and quantifying microplastics in wastewater, sediment and fauna.READ MORE
Fully Automated Sensitive Determination of Immunosuppressant Drugs in Whole Blood, using High Quality Internal StandardizationWhite Paper
Measurement of immunosuppressant drugs is essential during organ transplantation. Under-dosing can lead to organ rejection, while over-dosing can cause serious toxicity.READ MORE
8 Reasons why it’s Time to Upgrade to Automated ImagingWhite Paper
Why automated image analysis is rapidly replacing manual microscopy for characterizing particle shape and how combining it with Raman spectroscopy adds chemical identification.READ MORE